$\textbf{Website:} \ www.thechemopharmalaboratories Itd.com \ \bullet \ \textbf{Email ID:} \ chemopharmalab@gmail.com$

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2018

| | T | (Rupees in Thousand) | | | |
|------------|--|----------------------|------------|-----------|------------|
| Sr. No. | Particulars | Quarter Ended | | | |
| | | 30th June | 31st March | 30th June | 31st March |
| | | 2018 | 2018 | 2017 | 2018 |
| | D | Unaudited | Unaudited | Unaudited | Audited |
| I | Revenue from Operations | | | | - |
| II | Other Income | 1,240 | 4,112 | 1,377 | 11,055 |
| III | Total Revenue (I + II) | 1,240 | 4,112 | 1,377 | 11,055 |
| IV | Expenses | | | | |
| | (1) Cost Materials consumed | - | - | - | - |
| | (2) Purchase of Stock-in-Trade | - | - | - | - |
| | (3) Changes in Inventories of Finished Goods, Work-in-Progress | - | - | - | - |
| | and Stock-in-Trade | | | | |
| | (4) Employee Benefits Expenses | 563 | 397 | 244 | 1,564 |
| | (5) Depreciation and Amortisation Expenses | - | 35 | - | 35 |
| | Other Expenses (Any Item exceeding 10% of the Total Expenses relating to continuing Operations to be shown seperately) | 601 | 66 | 165 | 417 |
| | i) Professional Charges | - | 256 | 67 | 991 |
| | ii) Share Registry Expenses | 1 | 23 | 15 | 100 |
| | iii) Annual Listing Fees | 310 | 1 | 298 | 315 |
| | iv) Travellling Expenses | 268 | - | - | 1 |
| | (7) Finance Costs | 1 | 1 | ı | ı |
| | Total Expenses | 1,742 | 777 | 789 | 3,422 |
| V | Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV) | (502) | 3,335 | 588 | 7,633 |
| VI | Exceptional Items | ı | ı | ı | ı |
| VII | Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI) | (502) | 3,335 | 588 | 7,633 |
| VIII | Extra Ordinary Items | - | - | - | 1 |
| IX | Profit/(Loss) before Tax (VII-VIII) | (502) | 3,335 | 588 | 7,633 |
| X | Tax Expenses | | | | |
| | (1) Current Tax | - | 1,450 | 5,177 | 1,450 |
| | (2) Tax Adjustment Previous Year | - | - | - | 5,177 |
| | (3) Deffered Tax | - | - | - | - |
| XI | Profit/(Loss) for the period from continuing operations (IX - X) | (502) | 1,885 | (4,589) | 1,006 |
| XII | Profit/(Loss) from discontinuing operations | 1 | 1 | ı | 1 |
| XIII | Tax Expenses of discontinuing operations | 1 | 1 | ı | 1 |
| XIV | Profit/(Loss) from discontinuing operations (after tax) (XII - XIII) | - | - | - | - |
| XV | Profit/(Loss) for the period (XI - XIV) | (502) | 1,885 | (4,589) | 1,006 |
| XVI | Other Comprehensive Income | , | , | (/=== / | , |
| | A (i) Itmes that will not be reclassified to profit or loss | | | | |
| | (ii) Income rax relating to items that will not be reclassified to profit or loss | | | | |
| | B (i) Itmes that will not be reclassified to profit or loss | | | | |
| | (ii) Income rax relating to items that will not be reclassified to | _ | _ | _ | _ |
| XVII | Total Comprehensive Income for the period (XV+XVI) | | | | |
| | (Comprising Profit (Loss) and Other Comprehensive Income for the period | (502) | 1,885 | (4,589) | 1,006 |
| XVIII | Earnings per Share : (1) Basic | 40.00 | 100 | (0.05) | |
| | (2) Diluted | (0.33) | 1.26 | (3.06) | 0.67 |

Notes:

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Unaudited Financial Results for the Quarter Ended 30.06.2018 have been reviewed by the Audit Committee in their Meeting held on 30.07.2018 and approved by the Board of Directors of its Meeting held on 30.07.2018. The Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- The Company is not having any Subsidary Company.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

FOR CHEMO PHARMA LABORATORIES LIMITED

ASHOK SOMANI DIRECTOR (DIN NO. - 03063364)



Place: Mumbai

Date: 30th July, 2018